Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era

Archives of Pediatrics and Adolescent Medicine

Volumn 163, Issue 2, 2009, Pages 164-171

  Nachman, Sharon A ^a,f   Chernoff, Miriam ^b   Gona, Philimon ^b   Van Dyke, Russell B ^c   Dankner, Wayne M ^d   Seage III, George R ^b   Oleske, James ^e   Williams, Paige L ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b Boston University   (United States)

^c TULANE UNIVERSITY   (United States)

^d DUKE UNIVERSITY   (United States)

^e UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^f STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT DISEASE; ADULT; ARTICLE; BIRTH DEFECT; BRAIN DISEASE; CHILD; CHILDHOOD DISEASE; CONDYLOMA; DYSPLASIA; EPILEPSY; ERYTHEMA MULTIFORME; FEMALE; FOLLOW UP; GYNECOLOGIC DISEASE; HEART DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; KIDNEY DISEASE; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MICROCEPHALY; NEPHROLITHIASIS; PANCREATITIS; PERIPHERAL NEUROPATHY; PREGNANCY DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERTO RICO; RETINITIS; SUBSTANCE ABUSE; UNITED STATES;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; FEMALE; GENITAL NEOPLASMS, FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 60149096053     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpedi.163.2.164     Document Type: Article

References (20)

1. Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis. 2002; 186(7):1023-1027.
2. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holm-berg SD. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27-34.
3. Culnane M, Fowler MG, Lee S, et al; PACTG and Protocol 076/219 Teams. Lack of long term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA. 1999;281(2):151-157.
4. Gortmaker SL, Hughes M, Cervia J, et al. The impact of protease inhibitor combination therapy on mortality among children and youth infected with HIV-1. N Engl J Med. 2001;345(21):1522-1528.
5. DanknerWM, Lindsey JC, Levin MJ; Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300, and 327. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J. 2001;20(1):40-48.
6. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-Infected children in the HAART era. JAMA. 2006;296(3):292-300.
7. Nachman S, Gona P, Dankner W, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics. 2005;115(4):e488-e494. http://pediatrics.aappublications.org/cgi/content/ abstract/115/4/e488.
8. Patel K, Hernan M, Williams P, etal; PACTG219/219C Study Team. Long-term effectiveness of highly active antiretroviral therapy (HAART) on the survival of children and adolescents infected with HIV-1. Clin Infect Dis. 2008;46(4):507-515.
9. Furrer H, Fux C. Opportunistic infections: an update. J HIV Ther. 2002;7(1):2-7.
10. Finkelstein DM, Williams PL, Molenberghs G, Feinberg J, Powderly WG, Kahn J, Dolin R, Cotton DJ. Patterns of opportunistic infections in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12(1):38-45.
11. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999;282(23):2220-2226.
12. Mondy K, Tebas P. Cardiovascular risks of antiretroviral therapies. Annu Rev Med. 2007; 58:141-155.
13. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care. 2007; 30(1):113-119.
14. Reveille JD, Williams FM. Infection and musculoskeletal conditions: rheumatologic complications of HIV infection. Best Pract Res Clin Rheumatol. 2006; 20(6):1159-1179.
15. Nwaobasi E, Oleske JM. Toxicities of antiretroviral therapy in children. AIDS Read. 2006; 16(10):537-540, 544-546, 549-550, 552-554.
16. Bozkurt B. Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical studies. Cardiovasc Toxicol. 2004; 4(3):243-260.
17. Brogly S, Williams P, Seage GR III, Oleske JM, Van Dyke R, McIntosh K. Antiretroviral treatment in pediatric HIV infection in the United States. JAMA. 2005; 293(18):2213-2220.
18. Williams PL, Storm D, Montepiedra G, et al; the PACTG 219C Team. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics. 2006; 118(6):e1745-e1757. http://www.pediatrics.org/cgi/doi/10.1542/peds.2006-0493.
19. Brogly SB, Watts DH, Ylitalo N, et al. Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health. 2007;97(6):1047-1052.
20. Richardson H, Franco E, Pintos J, Bergeron J, Arella M, Tellier P. Determinations of low risk and high risk cervical human papillomavirus infections in Montreal university students. Sex Transm Dis. 2000;27(2):79-86.